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Background: An in vitro model was developed to understand if celecoxib could synergize with Mitomycin C
(MMC), commonly used for the prevention of non-muscle invasive bladder cancer recurrence, and eventually
elucidate if the mechanism of interaction involves multi drug resistance (MDR) transporters.
Methods: UMUC-3, a non COX-2 expressing bladder cancer cell line, and UMUC-3-CX, a COX-2 overexpressing
transfectant, as well as 5637, a COX-2 overexpressing cell line, and 5637si-CX, a non COX-2 expressing silenced 5637
cell line, were used in the present study. The expression of COX-2 and MDR pumps (P-gp, MDR-1 and BCRP) was
explored through western blot. The anti-proliferative effect of celecoxib and MMC was studied with MTT test. Three
biological permeability assays (Drug Transport Experiment, Substrate Transporter Inhibition, and ATP cell depletion)
were combined to study the interaction between MDR transporters and celecoxib. Finally, the ability of celecoxib to
restore MMC cell accumulation was investigated.
Results: The anti-proliferative effect of celecoxib and MMC were investigated alone and in co-administration, in
UMUC-3, UMUC-3-CX, 5637 and 5637si-CX cells. When administered alone, the effect of MMC was 8-fold greater in
UMUC-3. However, co-administration of 1 μM, 5 μM, and 10 μM celecoxib and MMC caused a 2,3-fold cytotoxicity
increase in UMUC-3-CX cell only. MMC cytotoxicity was not affected by celecoxib co-administration either in 5637,
or in 5637si-CX cells. As a result of all finding from the permeability experiments, celecoxib was classified as P-gp
unambiguous substrate: celecoxib is transported by MDR pumps and interferes with the efflux of MMC. Importantly,
among all transporters, BCRP was only overexpressed in UMUC-3-CX cells, but not in 5637 and 5637si-CX.
Conclusions: The UMUC-3-CX cell line resembles a more aggressive phenotype with a lower response to MMC
compared to the wt counterpart. However, the administration of celecoxib in combination to MMC causes a
significant and dose dependent gain of the anti-proliferative activity. This finding may be the result of a direct
interaction between celecoxib and MDR transporters. Indeed, BCRP is overexpressed in UMUC-3-CX, but not in
UMUC-3, 5637, and 5637si-CX, in which celecoxib is ineffective.
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The natural history of non-muscle invasive bladder
carcinoma (NMIBC) may be characterized by multiple
recurrences according to patient risk stratification [1].
Following transurethral resection (TUR), endovesical
chemotherapy is recommended by clinical practice
guidelines in intermediate and high-risk patients [2].
Mitomycin C (MMC) is a potent DNA cross-linker
commonly used as a bladder instillation to reduce the like-
lihood of bladder cancer recurrence and/or progression
[3]. Nonetheless, early recurrence is common after MMC
treatment and may recognize several causes, such as
disease phenotype [1], the presence of residual tumor
following a TUR [4], as well as downstaging [5]. Another
possible cause may be the failure of cancer treatment due
to resistance to structurally unrelated chemotherapeutic
agents, also defined Multi Drug Resistance (MDR)
[6,7]. MDR is usually associated with a decreased
intracellular concentration of cytostatic drugs and
with the overexpression of ATP-Binding Cassette (ABC)
transporters, such as P-glycoprotein (P-gp), Breast Cancer
Resistance Proteins (BCRP) and Mutidrug Resistance
associated Proteins (MRPs) [8-10]. These transporters
cause the efflux of drugs and xenobiotics out from the
cells [11]. Interestingly, their overexpression has been
observed in urothelial cancer cells [12] and may be useful
for selecting patients with bladder cancer to be candidates
for neoadjuvant chemotherapy [13].
Cyclooxygenases (COX) are enzymes required for
the conversion of arachidonic acid to prostaglandins. As
COX-1 is constitutively expressed, COX-2 is highly
induced in response to inflammatory signals [14]. Although
specific COX-2 inhibitors were generated for pain relief
and for their anti-inflammatory properties, experimental
and translational studies have shown that COX-2 is
involved in carcinogenesis, finally encouraging clinical
testing [15]. Recently, COX-2 inhibitors have gained
attention as chemosensitizers when combined with
other agents [16,17]. This property may be exerted by
interference with the activity of membrane proteins
involved in MDR [18,19].
In the urinary bladder, COX-2 plays an important role
in the development of transitional cell hyperplasia
and carcinoma [20]; COX-2 expression in the urothelium
is associated with high tumor grade and stage, and is an
independent predictor of disease progression and
survival [21,22]. Although treating these patients with
endovesical MMC causes a reduction in the recurrence
and progression rates of NMIBC, disease relapse is still
high [2]. Since COX-2 inhibitors, such as celecoxib,
may sensitize cells to antineoplastic agents we sought
to investigate if there is an interaction between
celecoxib, MMC and MDR transporters in a human
bladder cancer cell line.Methods
Cell lines and cell culture
UMUC-3, 5637, TCC sup cells and J82 (ATCC, Manassas,
VA, USA), derived from human transitional cell carcinoma
of the bladder, were routinely cultured in MEM supp-
lemented with 10% fetal bovine serum, 2 mM glutamine,
100 U/mL penicillin, 100 μg/mL streptomycin, 1X NEAA
and 1 mM sodium pyruvate. All components were
purchased form Invitrogen Corportion (Cergy Pontoise,
France), in a humidified incubator at 37°C with a 5% CO2
atmosphere. Caco-2 (IRCCS “S. De Bellis”, Castellana
Grotte, Italy), MDCK-MDR1, MDCK-MRP1 (gift of Prof.
P. Borst, NKI-AVL Institute, Amsterdam, Netherlands) and
MDCK-BCRP cells (gift of Dr. A. Schinkel, NKI-AVL
Institute, Amsterdam, Netherlands) were grown in
DMEM medium with 10% heat-inactivated fetal calf
serum, 100 U/mL penicillin, 100 μg/mL streptomycin
and 2 mM L-glutamine (Invitrogen) in a humidified
incubator at 37°C with a 5% CO2 atmosphere. The
cells were trypsinized twice a week with trypsin/
ethylenediaminetetraacetic acid (EDTA) (0.05%/0.02%)
and the medium was changed twice a week.
Cell lines transfection
The pSG5-COX-2 plasmid, which contains a full-length
human COX-2 cDNA in the pSG expression vector [23],
was used for COX-2 transfection. The plasmid DNA was
introduced into UMUC-3 cells using Lipofectamine LTX
(Invitrogen). Briefly, 2.5 μg of plasmid DNA and 6.25 μl
of Lipofectamine LTX were combined in 500 μl of
OpTI-MEM*I reduced serum medium (Invitrogen)
and allowed to stand at room temperature for 30 minutes.
UMUC-3 cells were plated at 1X105 cells/well in six-well
plates. After overnight attachment, the Lipofectamine
mixture was applied to cells. After 5 hours of transfection,
the medium was removed and complete medium was
added. After 48 hours, geneticin G418 (Invitrogen) was
added to cells at a concentration of 800 mg/ml. Cell lines
were obtained from individual colonies using cloning
cylinders. UMUC-3-CX overexpressing cells were obtained
and were continuously cultured in complete medium with
the addition of 800 μg/ml G418.
Cell lines siRNA transfection
The COX-2 si RNA, target- specific 19–25 nt siRNA
designed to knock down gene expression, was used for the
inihibition of COX-2 expression in 5637 bladder cells.
The COX-2 siRNA (Santa Cruz Biotech., CA, USA)
was introduced into 5637 cells using siRNA Transfection
Reagent (Santa Cruz Biotech.) Briefly, 5 μl of siRNA and
5 μl of siRNA Transfection Reagent were combined in 1
ml of siRNA Transfection Medium (Santa Cruz) and
allowed to stand at room temperature for 30 minutes.
5637 cells were plated at 2X105 cells/well in six-well
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fection Reagent mixture was applied to cells. After 5 hours
of transfection, the medium was removed and complete
medium was added.
Prostaglandin E2 (PGE2) quantification
PGE2 concentration was determined in the culture
medium of UMUC-3, UMUC-3-CX, 5637, 5637si-CX,
TCC sup and J82, cells. The cells were seeded into
24-well plates in the absence and presence of
celecoxib (1- 5–50 μM) into a final volume of 500 μl/well
of standard growth medium and incubated at 37°C
for 24–48 h. After incubation time, the culture media
were removed to determine PGE2 levels with the
PGE2 monoclonal enzyme immunoassay kit (Cayman
Chemicals) according to the manufacturer’s protocol and
results are expressed in pg of PGE2/ml of medium.
Western immunoblotting
UMUC-3, UMUC-3-CX, 5637, 5637si-CX, TCC sup, and
J82 cells were washed with 10 mL phosphate-buffered
saline (PBS), scraped in 1 mL PBS and centrifuged for 1
min at 11,000g. Proteins were extracted from cells by
homogenization in radioimmunoprecipitation (RIPA)
buffer [0.5 M NaCl, 1% Triton X100, 0.5% NP40, 1%
deoxycolic acid, 3.5 mM sodium dodecyl sulfate (SDS),
8.3 mM Tris HCl pH 7.4, 1.6 mM Tris base] and treated
with 20% protease inhibitor cocktail (Sigma Aldrich,
St. Louis, MO, USA). They were sonicated and centrifuged
at 14,000 g for 15 min at 4°C and the protein content in
the supernatant was measured using the Bradford
method. 25–50 μg of protein extract was separated
electrophoretically on 8% SDS–polyacrylamide gel
electrophoresis (SDS–PAGE) and proteins electroblotted
onto a nitrocellulose membrane (Bio-Rad, Hercules, CA,
USA). Membranes were stained with 0.5% ponceau in 1%
acetic acid to confirm equal loading. After overnight
incubation of the membranes in blocking buffer (5%
non-fat dried milk, 0.1% Tween 20 in Tris-buffered salt
solution, TBS) they were incubated overnight with the
respective primary antibody directed against COX-2 (1:500
mouse monoclonal), P-gp (1:1000 mouse monoclonal),
MRP1 (1:1000 mouse monoclonal), BCRP (1:1000 mouse
monoclonal) diluted in blocking buffer. The COX-2
antibody was purchased from Cayman Chemical (Ann
Arbor, MI, USA), all other antibodies from Sigma-Aldrich.
Membranes were washed four times with 0.1% Tween 20
in TBS and then incubated with a peroxidase-conjugated
secondary antibody (Amersham, Buckinghamshire, UK)
for1 hr. After extensive rinsing in 0.1% Tween 20 in TBS,
protein–antibody complexes conjugated with peroxidise
were treated with enhanced chemoluminiscence (ECL-Plus,
Amersham) according to the manufacturer’s protocol and
exposed to a chemoluminescence film. The expression levelwas evaluated by densitometric analysis using Quantity
One software (Bio-Rad) and β-actin expression level was
used to normalize the sample values.
Flow cytometry
UMUC-3 and UMUC-3-CX cells were harvested,
washed twice in ice-cold PBS (pH 7.4), fixed in 4.5 mL
of 70% ethanol, and stored at −20°C. Fixed cells were
washed in ice-cold PBS once and incubated in 0.5 mL of
0.1% Tween 20 in PBS for 15 minutes at 25°C. To
analyze P-gp/MRP1/BCRP expression, UMUC-3 and
UMUC-3-CX cells were incubated O/N at 4°C with
monoclonal anti-BCRP in 0.5% Tween 20 and 1% FBS in
PBS. To determine the non-specific fluorescence due to
the fluorescein conjugated secondary antibody, UMUC-3
and UMUC-3-CX cells were incubated with an appropriate
isotype control (50 Ag/106 cells) in the same experimental
conditions (isotype control). After 15 minute incubation
with 0.5 mL of 0.5% FBS in PBS, cells were centrifuged and
washed once in 0.5 mL of 0.5% FBS in PBS. The pellet was
resuspended in 0.5% FBS in PBS in the presence of the goat
anti-mouse IgG fluorescein-conjugated affinity-purified
secondary antibody (Millipore, Billerica, MA, USA; 1:50)
and incubated for 1 hour at 4°C. After a wash step
with 0.5 mL of 0.5% FBS in PBS, cells were
centrifuged and incubated in 5 Ag/mL propidium iodide
overnight at 4°C. BCRP protein determination was done
using a FACScan flow cytometer (Becton Dickinson,
Franklin Lakes, NJ, USA). Fluorescence analysis was gated
to include single cells based on forward and side light
scatter and was based on the acquisition of data from
10,000 cells. Log fluorescence was collected and displayed
as single variable histograms. The data analysis was carried
out with the CellQuest software (Becton Dickinson).
Cell anti-proliferative effect
The cells were seeded into 96-well plates in the
absence and presence of known concentrations (0,1-
0,5-1-5-10-30-50 μM) of celecoxib (Pfizer, NY, USA)
or MMC (Kyowa, Dusseldorf, DE), alone and in co-
administration, added to a final volume of 200 μl/well
of standard growth medium and incubated at 37°C
for 48 h. Afterwords, 10 μl of 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazoliumbromide (MTT) freshly prepared
solution (5 mg/ml in PBS) (Sigma) was added in each well,
and the plate was incubated in a humidified atmosphere
5% CO2 at 37° for 3–4 h. MTT solution was removed and
200 μL of EtOH/DMSO (1:1) was added to each well to
dissolve the blue formazan solid crystals. The optical
density was measured at 570 nm and 650 nm wavelenghts
using Victor3 (PerkinElmer, Waltham, MA, USA). The
results are expressed as EC50 values, obtained from
non-linear iterative curve fitting by Prism v.3.0, GraphPad
software (GraphPad Software, Inc. San Diego, USA).
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In the following three experiments a Caco-2 cell monolayer
was used to evaluate P-gp transporter’s interaction with a
given compound. In the “drug transport experiment” the
ability of a compound to permeate a cellular monolayer is
tested. Both apical (AP)→basolateral (BL) flux and BL→A
flux are evaluated since their ratio determines the perme-
ability value: compounds with a permeability ratio > 2 do
not permeate, compared to compounds with a ratio < 2. In
the “[3H]Substrate transport inhibition” assay, a given com-
pound competes for P-gp with its known substrate, [3H]
vinblastine. If our compound (i.e. celecoxib) binds P-gp,
[3H]vinblastine will be displaced reducing residual radio-
activity. Finally, since P-gp is an ATPasic pump, the “Cell
ATP availability assay” will test if cells consume ATP in the
presence of a given compound. P-gp binding compounds
are transported out of the cell and produce ATP consump-
tion. Taken together, these assays allow us to define if a
compound is either a transporter’s substrate, inhibitor, or
modulator, according to Polli’s classification [24].
Preparation of caco-2 monolayer
Caco-2 cells were seeded onto a Millicell® assay system
(Millipore), where a cell monolayer is set in between a filter
cell and a receiver plate, at a density of 10,000 cells/well.
The culture medium was replaced every 48 h and the cells
kept for 21 days in culture. The Trans Epitelial Electrical
Resistance (TEER) of the monolayers was measured
daily, before and after the experiment, using an
epithelial voltohometer (Millicell® -ERS). Generally, TEER
values greater than 1000 Ω for a 21day culture, are
considered optimal.
Drug transport experiment
After 21 days of Caco-2 cell growth, the medium was
removed from filter wells and from the receiver plate,
which were filled with fresh HBSS buffer (Invitrogen).
This procedure was repeated twice, and the plates were
incubated at 37°C for 30 min. After incubation time, the
HBSS buffer was removed and drug solutions of
celecoxib, MMC and reference compounds, were added
to the filter well at various concentrations (1–100 μM),
while fresh HBSS was added to the receiver plate. The
plates were incubated at 37°C for 120 min. Afterwords,
samples were removed from the apical (filter well)
and basolateral (receiver plate) side of the monolayer to
measure the permeability [24]. The apparent permeability








VA = the volume (in mL) in the acceptor well;Area = the surface area of the membrane (0.11 cm2 of
the well);
time = the total transport time in seconds (7200 sec);
[drug]acceptor = the concentration of the drug
measured by ESI-MS analyses or U.V. spectroscopy;
[drug]initial = the initial drug concentration (1 × 10–4 M)
in the apical or basolateral wells.
[3H]Substrate transport inhibition
20 nM of [3H]vinblastine were added in each well to the
BL compartment, in the absence and in the presence of
P-gp inhibitors (from 200 nM to 400 μM). After 120 min
at 37°C, [3H]vinblastine’s appearance was monitored at
the AP compartment. At 120 min a 20 μL sample was
taken from the donor compartment to determine the
concentration of the residual radioligand at the end
of the experiment. Samples were analyzed using
LS6500 Beckman–Counter. For each compound, [3H]
vinblastine transport inhibition was calculated as
radioactivity difference between radioligand in the
presence and absence of the given compound. These
differences were expressed as inhibition rate at each
drug concentration. Finally, the half maximal effective
concentration (EC50) values were determined [25].
Cell ATP availability assay
Caco-2 cells were seeded into 96-well microplate in
100 μL of complete medium at a density 2×104 cells/well.
The plate was incubated O/N in a humidified atmosphere
(5% CO2 at 37°C). The medium was removed and 100 μL
of complete medium were added, in the presence or
absence of different concentrations of test compounds.
The plate was again incubated for 2 h in a humidified
atmosphere. Then, 50 μl of mammalian cell lysis solution
were added to all wells and the plate stirred for 5 min in
an orbital shaker. In all wells, 50 μl of substrate solution
were added, and the plate stirred for 5 min as above
reported. The plate was dark adapted for 10 min and the
luminescence measured in Victor3 (PerkinElmer) [26].
Calcein-AM experiment
The ability of celecoxib to interact with each transporter
and restore calcein-acetoxymethylester (calcein-AM) was
studied in a cell system represented by MDCK cells mono-
layers, specifically prepared to overexpress P-gp, MRP1 or
BCRP (MDCK-P-gp, MDCK-MRP1, and MDCK-BCRP).
The method was adapted from Eneroth et al. [27] and
Korjamo et al. [28] with minor modifications. Briefly, each
cell line was seeded into a black Cultureplate (PerkinElmer)
96/wells plate with 100 μl medium and allowed to become
confluent overnight. Test compounds were solubilized in
100 μl of culture medium and added. After incubation at
37°C for 30 min. Calcein-AM, a fluorescent dye, was added
in 100 μl of PBS to yield a final concentration of 2.5 μM.
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was read using Victor3 at excitation and emission
wavelengths of 485 nm and 535 nm, respectively.
After definition of the fluorescence basal level in untreated
cells, calcein-AM cell accumulation, was measured in the
presence of the tested compound (celecoxib). In treated
wells the increase of fluorescence as compared to
basal level was measured. The half maximal effective
concentration (EC50) values were determined by fitting
the fluorescence increase percentage versus log[dose] [29].
Intracellular mitomycin C accumulation
The time course of MMC intracellular accumulation
and its modulation by celecoxib were evaluated by flow
cytometry. For the purpose of the experiment, MMC
and celecoxib were added to UMUC-3 and UMUC-3
-CX cells at EC50 concentrations of the corresponding
cell lines (Table 1). After incubation, the cell medium
was removed and trypsin/EDTA was used to detach the
cells from the plates. Cells were harvested, washed twice
in ice-cold PBS (pH 7.4), and placed on ice (<1 hour) until
analysis. Analysis was performed using a 530/30 filter
(FL1-H [height of fluorescence intensity]). Fluorescence
measurements of individual cells were done with a Becton
Dickinson FACScan equipped with an UV argon laser.
Analysis was gated to include single cells, based on
forward and side light scatter, and was based on the
acquisition of data from 10,000 cells [30].
Statistical methodology
All the reported values are expressed as means ± standard
deviation (SD) from triplicate experiments. EC50 values
were obtained from non-linear interative curve fitting by
GraphPad, Prism. For variance estimation, t-test and
Wilcoxon test were used. Statistical differences in Table 1
and in Table 2 were determined by Mann–Whitney
unpaired test. Differences were considered statistically
significant when P values were <0.05. All the research
carried out and reported in the present manuscript was
reviewed and approved by the ethical committee of the
Ospedale Policlinico Consorziale of Bari, Italy.Table 1 Antiproliferative effect of CLX and MMC, alone and in
UMUC3 UMUC-3- CX
CLX 14.2 ± 0.7 16.3 ± 0.8
MMC 1.69 ± 0.09 13.0 ± 1.0 0.
CLX 1 μM + MMC 1.54 ± 0.1 6 ± 0.3 1.
CLX 5 μM + MMC 1.75± 0.07 5.7 ± 0.2 1
CLX 10 μM + MMC 1.9 ± 0.1 4 ± 0.18 1.
EC50 = the concentration of a compound where 50% of its maximal effect is observ
The EC50 values were obtained from non-linear iterative curve fitting by Prism v.3.0
Compounds were tested at escalating doses, starting from 0.1 μM to 50 μM. ResultsResults
Expression of COX-2 and ABC trasporters in bladder
cancer cells
COX-2 and ABC transporters expression was studied via
western blot in several bladder cancer cell lines (Figure 1).
As previously reported [15], UMUC-3 lacks COX-2
expression and was used to create UMUC-3-CX, a COX-2
overexpressing transfectant. Moreover, 5637 showed the
highest COX-2 levels among the tested bladder cancer
cells and was used to obtain a silenced non-expressing
5637si-CX cell line. Successful UMUC-3 transfection and
5637 silencing are shown in Figure 1. Among the ABC
transporters, P-gp expression was similar in wild type and
in transfected UMUC-3, but undetectable in the other cell
lines. MRP1 protein was neglectable in all cell lines.
Finally, BCRP levels were increased in UMUC-3-CX as
compared to UMUC-3, while remained undetectable in all
other cell lines. Additionally, COX-2 functional activity
was tested in all cells by measuring PGE2 production.
As expected, celecoxib administration caused a dose
dependent reduction of endogenous PGE2 secretion
in all, except COX-2 non-expressing cells (UMUC-3 and
5637si-CX) (Figure 2). Short-term (24 and 48 h) exposure
of our cell lines to celecoxib (0.1 μM to 50 μM) caused no
significant change in transporter’s expression as studied
by western blot (data not shown).
Mitomycin C anti-proliferative effect and intracellular
accumulation in UMUC-3 and UMUC-3-CX cells
The anti-proliferative effect of celecoxib and MMC were
investigated alone and in co-administration at 48 h, in
5637 and 5637si-CX cells (Figure 3), and in UMUC-3 and
UMUC-3-CX cells (Figure 4). Compounds were tested at
escalating doses, starting from 0.1 μM to 50 μM. Results
are expressed as EC50 and are shown in Table 1. Dose
response curves are shown in the corresponding figures.
When administered alone, MMC had a comparable
anti-proliferative effect both in 5637 and 5637si-CX
cells; in these cells celecoxib was unable to affect MMC
killing (Figure 3). However, in the same experimental
conditions, the effect of MMC was eight fold greater inco-administration at 48 h, in bladder cancer cell lines
5637 5637 si-CX TCC sup J82
EC50 (μM)
> 50 > 50 15.7 ± 0.50 11.6 ± 0.31
93 ± 0.04 0.62 ± 0.05 0.83 ± 0.07 0.64 ± 0.09
46 ± 0.10 0.59 ± 0.03 0.74 ± 0.08 0.48 ± 0.03
.31± 0.06 0.47 ± 0.01 0.68 ± 0.04 1.04 ± 0.10
68 ± 0.11 1.01 ± 0.20 1.08 ± 0.20 1.09 ± 0.10
ed.
, GraphPad software.
are expressed as EC50.
Table 2 Biological evaluation of MDR inhibitors and reference compounds
EC50 ± SEM,
a (μM)
Compounds Caco-2 [3H] vinblastine
transport inhibition
MDCK-MDR1 Calcein-AM MDCK-MRP1 Calcein-AM MDCK-BCRP Calcein-AM
Celecoxib 30 ± 2.0 46.9 ± 2.5 10.1 ± 0.5 24.1 ± 1.2
Mitomycin C 10 ± 0.5 N.D.b N.D.b N.D.b
MK-571c 2.85 ± 0.25
Verapamilc 20d 3.65 ± 0.2
aData ± SEM are the mean of three independent determinations (samples in triplicate).
bMitomycin C activity was not determined because in the experimental conditions quenched the spectroscopic properties of the probe.
cReference compounds for MDR pumps.
dSee Colabufo et al. [40].
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Importantly, the co-administration of 1 μM, 5 μM, and 10
μM celecoxib to MMC did not cause a significant increase
of MMC cytotoxicity in UMUC-3 cells (Figure 4C).
By contrast, in UMUC-3-CX cells, the anti-proliferative
activity of MMC was 2–3 fold improved by the co-
administration of celecoxib compared to MMC alone
(Table 1, and Figure 4D).
Since UMUC-3 transfection caused an overexpression of
BCRP in UMUC-3-CX cells, we sought to explore the
ability of celecoxib to interfere with the efflux of MMC. For
this purpose, flow cytometry was performed to study MMC
intracellular accumulation, both in UMUC-3 and UMUC-3
-CX cells. The cells were either treated one day with MMC
or celecoxib alone, or with both in co-administration using
the following sequential schedule: 1 day celecoxib, and
afterwords, 1 day MMC and celecoxib added to the
same plate (Figure 5). Importantly, celecoxib was
able to produce an increase of intracellular MMC
concentration only in UMUC-3-CX cells, as shown
by the right shift of the d curve as compared to the
c curve (Figure 5B). This effect was not seen in
UMUC-3 cells (Figure 5A).Celecoxib-transporter interacting mechanism
Three biological assays (Drug Transport Experiment,








Figure 1 Protein expression levels of COX-2, P-gp, MRP1 and BCRP in
determined by western blot. Cell lysates were obtained from exponentia
antibodies. Immunoblotting with an antibody to β-actin was used to ensurwere combined to establish if there was an interaction
between P-gp and celecoxib. In the drug transport
experiment, a Caco-2 cell monolayer was used to
determine the apparent permeability (Papp) of celecoxib,
both as basolateral-apical flux (B→A) and apical-basolateral
flux (A→B). Celecoxib displayed Papp A→B = 137 nm/sec,
Papp B→A = 1027 nm/sec, and a 7.5 BA/AB ratio.
This result suggests that celecoxib is effluxed by P-gp.
Indeed, compounds displaying BA/AB ratio > 2 are
linked and flipped to the extra cellular compartment
by pumps, while drugs with BA/AB ratio < 2 are not
transported. Moreover, the Subtrate Transporter Inhibition
experiment was performed to study the modulating
effect of celecoxib on [3H]vinblastine transport. Compared
to Verapamil, which is the reference compound for
this experiment, celecoxib had a similar EC50 value
(EC50 = 30 ± 2.0 μM) (Table 2). Finally, when tested
in Caco-2 cells to monitor ATP cell depletion, celecoxib
decreased ATP levels in a time- and dose-dependent
fashion. As a result of all finding combined, celecoxib
should be classified as P-gp unambiguous substrate [24].Celecoxib in MDCK cells overexpressing P-gp or BCRP or
MRP1 pumps
In MDCK-P-gp, in MDCK-MRP1 and in MDCK-BCRP
cells the ability of celecoxib to restore calcein-AM cell accu-
mulation was tested. This dye, calcein-acetoxymethylester,5637si
-CX
TCCsup J82
UMUC3, UMUC-3-CX, 5637, 5637si-CX, TCCsup, and J82, as
lly growing cells and subjected to immunoblotting with appropriate













































Figure 2 Secretion of prostagladin E2 in the culture medium of a selection of bladder cancer cell lines. PGE2 in cell supernatant was
determined by enzyme immunoassay after treatment with or without known concentrations (0 - 1- 5–50 μM) of Celecoxib for 24 and 48 h.
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substrate that diffuses across the plasma membrane
into the cell where is hydrolyzed into highly fluores-
cent calcein by endogenous cytoplasmic esterases.
This fluorescent compound is not effluxed by P-gp,
MRP1, BCRP and it cannot cross the cell membrane
via passive diffusion because of its hydrophilie.
Therefore, in the presence of an MDR transporter
modulator, calcein retention and a rapid fluorescence
increase is monitored (Figure 6). In Table 2, calcein cell
accumulation is plotted vs Log[celecoxib] and the
following results are displayed: in MDCK-P-gp cells EC50 =
46.9 ± 2.5 μM, in MDCK-MRP1 EC50 = 10.1 ± 0.5 μM,
and in MDCK-BCRP EC50 = 24.1 ± 1.2 μM. Com-
pared to the reference compounds, these findings
confirm that celecoxib is a substrate for P-gp, MRP1
and BCRP pumps.Discussion
In recent years, there has been an interest to investigate
the potential link between COX-2 expression and the
development of MDR in multiple tumors, including
urothelial cancer [21,22]. A direct causal link between
the activation of the COX-2/PGE2 signal pathway and
the up-regulation of all three ABC transporters has been
documented [31-35] and supports the strong correlation
between COX-2 and MDR1/P-gp expression seen in
several tumor specimens [36-38]. Overexpression of P-gp
has been found in human bladder cancer cells selected by
drug resistance against P-gp-targeting drugs [39-41]. In
patients with bladder cancers, expression of P-gp is
often increased after chemotherapeutic treatment [42].
Prophylactic intravesical instillation of MMC, doxorubicin
and epirubicin has been useful for reducing recurrence of
NMIBC; however, recurrence rates are still high and
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Figure 3 Antiproliferative effect of celecoxib and MMC administered alone at increasing doses (0,1 - 0,5 - 1–5 - 10–30 - 50 μM) (A, B).
Antiproliferative effect of MMC alone and in co-administration with known concentrations of celecoxib (C, D). All experiments conducted after
48 h of incubation in 5637 (A, C) and in 5637si-CX (B, D) cells.
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Figure 4 Antiproliferative effect of celecoxib and MMC administered alone at increasing doses (0,1 - 0,5 - 1–5 - 10–30 - 50 μM) (A, B).
Antiproliferative effect of MMC alone and in co-administration with known concentrations of celecoxib (C, D). All experiments conducted after
48 h of incubation in UMUC-3 (A, C) and in UMUC-3-CX (B, D) cells.
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http://www.molecular-cancer.com/content/12/1/47progression to more invasive disease is not affected even
after intensive intravesical chemotherapy [43].
In this study we developed an in vitro bladder cancer
model to study if COX-2 inhibitors can modulate tumor
resistance to MMC by interfering with the activity of
membrane transporter proteins of the ABC family. For this
purpose we used UMUC-3 cells, constitutively lacking
COX-2 expression, and UMUC-3-CX cells, in which
COX-2 is overexpressed. When MMC was administered
alone, UMUC-3-CX cells resulted resistant to MMC
killing. However, for the first time we showed that pre-
treatment with a selective COX-2 inhibitor, celecoxib,
caused a significant and dose dependent increase in the
cytotoxic activity of MMC. Interestingly, in UMUC-3 cells
MMC activity was not affected by celecoxib. Moreover,
compared to UMUC-3, we found that forced COX-2
overexpression in UMUC-3-CX cells increased PGE2
production and up-regulated BCRP, one of the transporters
involved in MDR. These data were confirmed by the
observation of an increase in intracellular concentration
of MMC when UMUC-3-CX cells were co-treated with
celecoxib. Again, intracellular MMC concentration was
not affected by celecoxib in UMUC-3 cells. Although
several causes may be taken into account it has beenshown that ABC transporters, such as BCRP, induce drug
resistance by promoting drug efflux out of the cells [44].
Indeed, when the cytotoxicity properties of MMC
were studied in a cell line completely lacking any
ABC transporter expression, such as 5637 and 5637si-CX
cells, celecoxib administration was unable to affect MMC
killing. Assuming a causal link between COX-2 expression
and MDR, COX-2 inhibitors would be expected to
prevent ABC transporters induction and sensitize cells to
antineoplastic agents. This has been previously shown in
Caco-2 cells where indomethacin, nimesulide and
naproxen directly reduced MRP1 expression and P-gp
relative amount and function [45]. Similarly, in human
lung cancer cells celecoxib was shown to downregulate
the expression of MRP1 [19].
Although COX-2 enzyme inhibition could not be
excluded in our experimental model, we sought to
investigate if the effect seen in UMUC-3-CX cells
after celecoxib administration could be the result of a
direct interaction between celecoxib and any of the
three transporters involved in MDR. To explore this
hypothesis specific biological assays were performed
to demonstrate that celecoxib is a substrate for the





a. Untreated cells control
b. 1day Celecoxib treated cells
c. 1day Mitomycin C treated cells






a. Untreated cells control
b. 1day Celecoxib treated cells
c. 1day Mitomycin C treated cells
d. 1 day Celecoxib + 1day Mitomicyn C treated cells
Figure 5 Flow cytometry analysis to study the time course of MMC intracellular accumulation and its modulation by celecoxib in
UMUC-3 (A) and UMUC-3-CX (B). In both cases, cells were treated one day with MMC (1.69 μM) or celecoxib (14.2 μM) alone, or with both in
co-administration (MMC 1.69 μM + celecoxib 14.2 μM). Celecoxib causes an increase in the intracellular concentration of MMC in UMUC-3-CX, but
not in UMUC-3 cells.
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http://www.molecular-cancer.com/content/12/1/47demonstrate that celecoxib is effluxed by P-gp, BCRP and
MRP1 pumps and causes a time- and dose-dependent ATP
cell depletion in Caco-2 cells. Further, celecoxib competes
with and may inhibit the transport of other reference drugs
(vinblastine in our experimental model) (Table 2). Finally,
the ability of celecoxib to restore Calcein-AM cell accumu-
lation in MDCK-P-gp, MDCK-MRP1 and MDCK-BCRP
cells suggests that celecoxib is a substrate for all the trans-
porters tested in our study. Thus, the increase in MMCconcentration seen in UMUC-3-CX after co-administration
with celecoxib may be the result of a transporter-celecoxib
interaction. As a hypothesis, since BCRP was the only
transporter overexpressed by UMUC-3-CX cells, a
BCRP-celecoxib interaction may justify the greater
anti-proliferative activity obtained when MMC and
celecoxib were co-administered (Figures 3 and 4).
Our findings are in agreement with previous studies


































C C C AMCelecoxib Calcein Calcein-AM
Figure 6 Schematic view of the mechanism of calcein cellular retention in the absence (A) and in the presence (B) of an MDR pump
substrate, such as celecoxib.
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Wijngaarden and co-workers proposed that the effects of
celecoxib were most likely mediated by inhibition of NF-kb
and not related to COX-2 or the activity of the ABC trans-
porters P-gp, MRP1 and ABCG2 [46]. Likewise, Ye et al.
found that indomethacin and SC236, a COX-2-selective
inhibitor, sensitized human hepatocellular carcinoma
HepG2 cells to the cytotoxicity of doxorubicin by signifi-
cantly increasing doxorubicin intracellular accumulation;
however, the effects were not reversed by prostaglandin E2,
implicating a COX-independent mechanism [47]. Taken
together, these findings suggest that COX-2-selective
inhibitors may enhance the effect of certain anti-cancer
agents and overcome drug resistance through mechanisms
that by-pass the COX-2 cascade.
Many reports examining the clinical benefits of COX-2
inhibitors and nonsteroidal anti-inflammatory drugs
(NSAIDs) have addressed the role of these compounds in
bladder chemoprevention. In vitro and in vivo research
suggests that NSAIDs hinder growth and survival of
bladder cancer cells [48,49], however, epidemiologic
studies investigating the association between non selective
NSAIDs and bladder cancer have been conflicting, with
two large cohort studies suggesting that non-aspirin
NSAIDs, but not aspirin, may protect from bladder cancer
[50,51]. Such conflicting data have discouraged the
scientific community to promote prospective clinical
testing of aspirin or acetic acids (indomethacin,
sulindac) in patients with NMIBC. On the other hand, the
body of evidence pointing to the role of COX-2 pathway
in the development of bladder cancer is compelling and
supported by several epidemiologic studies [51]. More
recently, COX-2 selective inhibitors have been the focus
of much scrutiny in terms of cardiovascular risk. Of such
inhibitors, celecoxib is thought to have a better safety
profile, and has been tested in patients with NMIBC, andclinical trials are under way. Sabichi et al. recently
reported the results of a phase IIb randomized controlled
trial of celecoxib to prevent recurrence following TUR in
146 patients with NMIBC [52]. Although the primary
endpoint (time to recurrence) did not reach statistical
significance, the results support a beneficial effect of
celecoxib in such patients. For the ultimate interpretation
of these results, the ongoing phase III randomized
controlled Bladder COX Inhibition Trial (BOXIT) of the
same daily dose of celecoxib versus placebo is being
conducted [www.cancerresearchuk.org].
We recognize this is a pilot study, in which we show
that celecoxib is a substrate for ABC transporters and
may enhance the activity of cytotoxic drugs such as MMC.
However, translational studies and, more importantly,
ongoing and future clinical trials will have to confirm
the preclinical potential of celecoxib and other COX-2
inhibitors in NMIBC.
Conclusions
Compared to the wt counterpart, the UMUC-3-CX
cell line resembles a more aggressive phenotype with
a higher BCRP protein expression and a low response to
MMC. Interestingly, the cytotoxic activity is regained when
MMC is administered in combination with celecoxib.
Although COX-2 enzyme inhibition cannot be excluded,
this result may partly depend on a direct interaction
between celecoxib and any of the transporters involved in
MDR. Indeed, we have shown that celecoxib is a
substrate for P-gp/BCRP/MRP1 transporters and may
modulate their activity. These findings and others
from recent reports imply that the therapeutic approach of
combining conventional chemotherapy with selective
COX-2 inhibitors seems promising and warrants
prospective clinical evaluation in patients with NMIBC in
which COX-2 is overexpressed.
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